Kirchheiner Kathrin, Nout Remi A, Czajka-Pepl Agnieszka, Ponocny-Seliger Elisabeth, Sturdza Alina E, Dimopoulos Johannes C, Dörr Wolfgang, Pötter Richard
Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna/General Hospital of Vienna, Austria.
Department of Clinical Oncology, Leiden University Medical Center, The Netherlands.
Gynecol Oncol. 2015 Mar;136(3):415-23. doi: 10.1016/j.ygyno.2014.10.031. Epub 2014 Nov 20.
To evaluate health-related quality of life (HR-QoL) and patient reported symptoms (PRS) before, during and early after treatment with external-beam radiotherapy (EBRT), chemotherapy and image-guided adaptive brachytherapy (IGABT) for locally advanced cervical cancer.
In fifty consecutive patients, HR-QoL and PRS were prospectively assessed with the EORTC-QLQ-C30+CX24 questionnaire prior to and during treatment, one week after IGABT and three months thereafter. HR-QoL was compared to an age-matched, female normative reference population. Prevalence rates of individual PRS are presented and defined as "substantial", if reported as "quite a bit" or "very much".
Global health status and physical and role functioning show a highly significant decline during treatment (p≤0.001), before returning to near the baseline levels three months after end of treatment. Compared to the reference population, the global health status and emotional and role functioning remain impaired. The most frequently reported substantial PRS during active treatment are: fatigue (78%), diarrhea (68%), urinary frequency (60%) and nausea (54%); these recover to some degree three months after end of treatment. However, fatigue remains increased (50%) and an onset of hot flashes (44%), sexual worries (38%) and limb edema (22%) is observed.
Several impairments in HR-QoL and PRS were found during definitive radio(chemo)therapy with IGABT, with different patterns of progress over time and signs of recovery three months thereafter, although some aspects of functional HR-QoL remain impaired. These findings support a comprehensive patients' counseling on what to expect and how to organize professional, social and family life and plan additional support during this period.
评估局部晚期宫颈癌患者在接受体外放射治疗(EBRT)、化疗及图像引导自适应近距离放射治疗(IGABT)之前、治疗期间及治疗后早期的健康相关生活质量(HR-QoL)和患者报告的症状(PRS)。
连续纳入50例患者,在治疗前、治疗期间、IGABT治疗后1周及此后3个月,采用欧洲癌症研究与治疗组织生活质量核心问卷(EORTC-QLQ-C30)+CX24问卷对HR-QoL和PRS进行前瞻性评估。将HR-QoL与年龄匹配的女性正常参考人群进行比较。呈现个体PRS的患病率,并将报告为“相当多”或“非常多”的情况定义为“严重”。
在治疗期间,总体健康状况以及身体和角色功能显著下降(p≤0.001),在治疗结束后3个月恢复至接近基线水平。与参考人群相比,总体健康状况以及情感和角色功能仍受损。在积极治疗期间最常报告的严重PRS为:疲劳(78%)、腹泻(68%)、尿频(60%)和恶心(54%);这些症状在治疗结束后3个月有一定程度的恢复。然而,疲劳仍增加(50%),并出现潮热(44%)、性方面的担忧(38%)和肢体水肿(22%)。
在采用IGABT的根治性放(化)疗期间发现了HR-QoL和PRS的多种损害,随时间推移有不同的进展模式,且在3个月后有恢复迹象,尽管功能性HR-QoL的某些方面仍受损。这些发现支持对患者进行全面的咨询,告知其预期情况以及如何安排职业、社交和家庭生活,并在此期间计划额外的支持。